Literature DB >> 32932111

The ONTAI study - a survey on antimicrobial dosing and the practice of therapeutic drug monitoring in German intensive care units.

U Liebchen1, M Paal2, C Scharf3, I Schroeder3, B Grabein4, J Zander5, C Siebers6, M Zoller3.   

Abstract

PURPOSE: Optimization of antibiotic therapy is still urgently needed in critically ill patients. The aim of the ONTAI survey (online survey on the use of Therapeutic Drug Monitoring of antibiotics in intensive care units) was to evaluate which strategies intensive care physicians in Germany use to improve the quality of antibiotic therapy and what role a Therapeutic Drug Monitoring (TDM) plays.
METHODS: Among the members of the German Society for Anaesthesiology and the German Society for Medical Intensive Care Medicine and Emergency Medicine, a national cross-sectional survey was conducted using an online questionnaire.
RESULTS: The questionnaire was completely answered by 398 respondents. Without TDM, prolonged infusion was judged to be the most appropriate dosing regimen for beta lactams. A TDM for piperacillin, meropenem and vancomycin was performed in 17, 22 and 75% of respondents, respectively. For all beta lactams, a TDM was requested more often than it was available. There was great uncertainty as to the optimal pharmacokinetic/pharmacodynamic index for beta-lactams. 86% of the respondents who received minimal inhibitory concentrations adapted the therapy accordingly.
CONCLUSION: German intensive care physicians are convinced of TDM for dose optimization. However, practical implementation, the determination of MICs and defined target values are still lacking.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Beta-lactams; Intensive care unit; Minimal inhibitory concentration; Pharmacokinetics/pharmacodynamics; Survey; Therapeutic drug monitoring

Mesh:

Substances:

Year:  2020        PMID: 32932111     DOI: 10.1016/j.jcrc.2020.08.027

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  11 in total

Review 1.  [Therapeutic drug monitoring and pharmacokinetic models as a strategy for rational antibiotic therapy in intensive care patients].

Authors:  Lea Marie Schatz; Michael Zoller; Christina Scharf; Uwe Liebchen
Journal:  Anaesthesiologie       Date:  2022-06-15

2.  Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools.

Authors:  Ferdinand Anton Weinelt; Miriam Songa Stegemann; Anja Theloe; Frieder Pfäfflin; Stephan Achterberg; Franz Weber; Lucas Dübel; Agata Mikolajewska; Alexander Uhrig; Peggy Kiessling; Wilhelm Huisinga; Robin Michelet; Stefanie Hennig; Charlotte Kloft
Journal:  Antibiotics (Basel)       Date:  2022-06-02

3.  Target Site Pharmacokinetics of Meropenem: Measurement in Human Explanted Lung Tissue by Bronchoalveolar Lavage, Microdialysis, and Homogenized Lung Tissue.

Authors:  Michael Paal; Christina Scharf; Ann Katrin Denninger; Luis Ilia; Charlotte Kloft; Nikolaus Kneidinger; Uwe Liebchen; Sebastian Michel; Christian Schneider; Sebastian Schröpf; Carina Schuster; Michael Vogeser; Ferdinand Weinelt; Johannes Zander; Michael Zoller; Ines Schroeder
Journal:  Antimicrob Agents Chemother       Date:  2021-09-27       Impact factor: 5.191

4.  Combination of Pharmacokinetic and Pathogen Susceptibility Information To Optimize Meropenem Treatment of Gram-Negative Infections in Critically Ill Patients.

Authors:  Uwe Liebchen; Ferdinand Weinelt; Jette Jung; Robin Michelet; Christina Scharf; Ines Schroeder; Michael Paal; Michael Zoller; Charlotte Kloft
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.938

5.  Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study.

Authors:  Erin F Barreto; Andrew D Rule; Mohammad H Alshaer; Jason A Roberts; Mohd Hafiz Abdul Aziz; Marc H Scheetz; Kristin C Mara; Paul J Jannetto; Ognjen Gajic; John C O'Horo; Kasey R Boehmer
Journal:  Implement Sci Commun       Date:  2021-03-24

6.  Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients.

Authors:  Uwe Liebchen; Marian Klose; Michael Paal; Michael Vogeser; Michael Zoller; Ines Schroeder; Lisa Schmitt; Wilhelm Huisinga; Robin Michelet; Johannes Zander; Christina Scharf; Ferdinand A Weinelt; Charlotte Kloft
Journal:  Antibiotics (Basel)       Date:  2021-04-20

7.  Beta-lactam dosing during continuous renal replacement therapy: a survey of practices in french intensive care units.

Authors:  Elodie Matusik; Justine Lemtiri; Guillaume Wabont; Fabien Lambiotte
Journal:  BMC Nephrol       Date:  2022-01-29       Impact factor: 2.388

Review 8.  β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value.

Authors:  Thomas J Dilworth; Lucas T Schulz; Scott T Micek; Marin H Kollef; Warren E Rose
Journal:  Crit Care Explor       Date:  2022-07-05

9.  Barriers and facilitators for therapeutic drug monitoring of beta-lactams and ciprofloxacin in the ICU: a nationwide cross-sectional study.

Authors:  Inge Spronk; Birgit C P Koch; Tim M J Ewoldt; Alan Abdulla; Puck van den Broek; Nicole Hunfeld; Soma Bahmany; Anouk E Muller; Diederik Gommers; Suzanne Polinder; Henrik Endeman
Journal:  BMC Infect Dis       Date:  2022-07-13       Impact factor: 3.667

10.  Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing-A Translational Example for Intensive Care Units.

Authors:  Ferdinand Anton Weinelt; Miriam Songa Stegemann; Anja Theloe; Frieder Pfäfflin; Stephan Achterberg; Lisa Schmitt; Wilhelm Huisinga; Robin Michelet; Stefanie Hennig; Charlotte Kloft
Journal:  Pharmaceutics       Date:  2021-12-10       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.